Patents by Inventor Raquel Martins
Raquel Martins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11672839Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: GrantFiled: December 4, 2017Date of Patent: June 13, 2023Assignees: TECHNECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR—INDUSTRIA TECNICA FARMACEUTICA, SAInventors: Sofia Valker Córte-Real, Miguel Ângelo Costa Garcia, Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa
-
Publication number: 20210187046Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains and cocktails thereof, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: ApplicationFiled: December 18, 2020Publication date: June 24, 2021Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR - INDUSTRIA TECNICA FARMACEUTICA, S.A.Inventors: Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa, Daniela Jones Dias, Ana Filipa Martins, Miguel Ângelo da Costa Garcia, Sofia Volker Côrte-Real
-
Publication number: 20190290709Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.Type: ApplicationFiled: December 4, 2017Publication date: September 26, 2019Inventors: Sofia Valker Côrte-Real, Miguel Ângelo Costa Garcia, Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa
-
Patent number: 9737579Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: July 22, 2016Date of Patent: August 22, 2017Assignees: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar—Industria Tecnica Farmaceutica, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20160317590Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: July 22, 2016Publication date: November 3, 2016Inventors: Miguel Ångelo DA COSTA GARCIA, Carlos Jorge SOUSA DE SÃO JOSÉ, Clara Isabel RODRIGUES LEANDRO, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel MARTINS BARBOSA
-
Patent number: 9399049Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: November 17, 2015Date of Patent: July 26, 2016Assignees: Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar-Industria Tecnica Farmaceutica, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20160074446Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: November 17, 2015Publication date: March 17, 2016Inventors: Miguel Ângelo DA COSTA GARCIA, Carlos Jorge SOUSA DE SÃO JOSÉ, Clara Isabel RODRIGUES LEANDRO, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel MARTINS BARBOSA
-
Patent number: 9222077Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: GrantFiled: September 19, 2011Date of Patent: December 29, 2015Assignees: Tecnifar—Industria Tecnica Farmaceutica, S.A., Technophage, Investigacao E Desenvolveimento Em Biotecnologia, SAInventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20140079671Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.Type: ApplicationFiled: September 19, 2011Publication date: March 20, 2014Applicants: TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA, TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A.Inventors: Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa
-
Publication number: 20100318187Abstract: A method for producing a polymeric surface-structured substrate includes: (a) preparing a first precursor substrate that is nanostructured on at least one surface with inorganic nanoparticles, (b) coating a hardenable substrate material for a second substrate different from the first precursor substrate material onto the nanostructured surface of the precursor substrate, wherein the hardenable substrate material includes cross-linkable monomeric, oligomeric or polymeric starting components for producing a polymeric substrate, (c) hardening the hardenable substrate material to obtain a polymeric substrate, and (d) separating the precursor substrate from the polymeric substrate as a result of which a polymeric substrate nanostructured with nanoparticles and including a polyurethane is obtained.Type: ApplicationFiled: June 11, 2010Publication date: December 16, 2010Applicant: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Sebastian Kruss, Joachim P. Spatz, Raquel Martin
-
Publication number: 20080185250Abstract: A case for containing at least partly compressible articles comprises an outer shell which can be opened and closed and defines a cavity therewithin, and having an attachment member or members secured to the outer shell inside the cavity. A number of compression bags are contained within the shell cavity and are detachably retained by the attachment members such as to maintain a relative position with respect to one another within the case. Each of the compression bags includes is air impervious when sealed and can received the articles within the enclosure defined therein, and includes a one-way valve allowing air to be removed from the enclosure within the bag, thereby creating at least a partial vacuum in the enclosure which compresses the articles within the bag.Type: ApplicationFiled: December 12, 2007Publication date: August 7, 2008Inventors: Norberto Martins, Raquel Martins